101 / 1631
PD-1 Blockade With Pembrolizumab in Patients With cHL After
BV Failure: Safety, Efficacy, and Biomarker Assessment
•
ORR 65% (n= 31), CR 16% (n=5), PR (48%) n=15, and SD
(23%) n=7
•
With a median follow-up of 9.7 (1.3-17.5) months, median DOR
not been reached (0+ to 13.4+ months)
•
As of the data cut-off,
14 patients (45%) remained on
treatment
; 2 (6%) patients discontinued for toxicity, 12 (39%)
for progression, and 3 (10%) for other reasons
•
Of the 20 responses, 14 are ongoing
Armand P, et al.
Blood.
2015;126:Abstract 584.